Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.42 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.35 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.35 |
| ▸ | DHFR | P00374 | 5/20 | 0.33 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19939694 | 0.84 | NUDT1 (0.40) | NUDT1RPS6KA2KDM4EMEN1NPC1 | |
| SCHEMBL19939692 | 0.82 | NUDT1 (0.39) | NUDT1RPS6KA2KDM4EMEN1NPC1 | |
| SCHEMBL19939698 | 0.79 | NUDT1 (0.64) | NUDT1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL18645376 | 0.79 | NUDT1 (0.64) | NUDT1RPS6KA2ESR1ESR2KDM4E | |
| SCHEMBL19939691 | 0.78 | NUDT1 (0.45) | NUDT1RPS6KA2KDM4EMEN1NPC1 | |
| SCHEMBL19939690 | 0.78 | NUDT1 (0.45) | NUDT1KDM4EMEN1NPC1ALDH1A1 | |
| SCHEMBL31430479 | 0.78 | RPS6KA2 (0.48) | NUDT1RPS6KA2ESR1ESR2KDM4E | |
| SCHEMBL19939689 | 0.75 | NUDT1 (0.42) | NUDT1ESR1ESR2KDM4EMEN1 | |
| SCHEMBL19939701 | 0.75 | NUDT1 (0.42) | NUDT1ESR1ESR2KDM4EMEN1 | |
| SCHEMBL19939696 | 0.74 | NUDT1 (0.41) | NUDT1KDM4EMEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | NUDT1 2660/4885RPS6KA2 198/4885ESR1 2225/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | NUDT1 2660/4885RPS6KA2 198/4885ESR1 2225/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | NUDT1 2660/4885RPS6KA2 198/4885ESR1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.